Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 4Gastrointestinal 4Breast 4Tumor-Agnostic 2Other solid neoplasm 2Gynecologic 2Sarcoma 1Myeloid 1Lymphoid 1

Conditions

Ovarian Carcinosarcoma 1Advanced Ovarian Cancer 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Antineoplastic Agents × Gynecologic × Clear all
NCT03651206 2026-06-01

ROCSAN

ARCAGY/ GINECO GROUP

Phase 2/3 Recruiting
138 enrolled
GynecologicSarcoma

Ovarian Carcinosarcoma

NCT03611179 2018-08-02

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Assiut University

Phase 2 Unknown
40 enrolled
Gynecologic

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡